Matinas Biopharma Holdings, Inc. · AMEX:MTNB
Matinas Biopharma — Corporate Update (January 2023)
13 slides from Matinas Biopharma's corporate update, Jan 30, 2023
Slide 1: 2023 Business Update and Strategic Outlook
2023 Business Update and Strategic Outlook January 30, 2023 MATINAS ~ BIOPHARMA
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the our business activities, our strategy and plans, our collaborations with BioNTech and National Resilience, th
Slide 3: 2022 In Review
2022 In Review LNCs and The Future of Medicine Agenda MAT2203 Update Matinas Investment Thesis and Upcoming Catalysts
Slide 4: 2022 Success Increased Confidence in LNC Platform Potential
2022 Success Increased Confidence in LNC Platform Potential Research Collaboration ENACT achieved with National q Resilience as a primary and potential platform ACHIEVED secondary partner in nucleic clarity from FDA endpoints acid space . and EMA in Phase 2 trial of Excluslve on MAT2203 WEEN a Resea
Slide 5: The Future of Medicine is Delivering Therapies Affecting Genetic Mechanisms
The Future of Medicine is Delivering Therapies Affecting Genetic Mechanisms mRNA DNA MODALITY Shorter term expression Long term expression but CONSIDERATIONS without need for genome integration concerns over genome integration * Not orally available * Not orally available * Currently delivered via L
Slide 6: LNCs Have the Potential to Disrupt Gene/Nucleic Acid Delivery
LNCs Have the Potential to Disrupt Gene/ Nucleic Acid Delivery VALUE INTERNAL ; Pipeline Focus Extrahepatic targeting of ASOs/siRNA ASOs/siRNA ASOs / siRNA Small ~ 20 bases in length Double stranded EXTERNAL Oral delivery Partnerships of mRNA Improved stability of mRNA Improved safety of DNA wa BION
Slide 7: Matinas Is Driving Forward with Both Small and Large Oligo Delivery
Matinas Is Driving Forward with Both Small and Large Oligo Delivery 2H 2022 1H 2023 2H 2023 Ee ee In vitro delivery S S) Multiple in-vivo LARGE OLIGOS biodistribution studies DNA/mRNA @ Multiple in-vivo SMALL OLIGOS biodistribution studies ASOs/siIRNA
Slide 8: LNC-mRNA Formulations Remain Biologically Active for at least 10 weeks at 4°C
LNC-mRNA Formulations Remain Biologically Active for at least 10 weeks at 4°C Evaluation at later time points ongoing RNA2 10 Week 4°C Stability m= Week 0 m= Week 5 m= Week 10 100 62ng mRNA | 18 hrs post incubation | HeLa cells Percent of GFP+ Live Cells or 3° LNP mRNA COVID vaccine stability at 2-8
Slide 9: Advancing MAT2203 Through Non-Dilutive Dollars
Advancing MAT2203 Through Non-Dilutive Dollars ar Wo PARTNER(s) * Greatest commercial opportunity is focused on IFI pathway « Additional focus on COGs and projected sales margins * Phase 3 crypto data of lower interest except for regulatory advantages in streamlining IFI study ° Regulatory exclusivi
Slide 10: Phase III IFI Study - Preliminary Design
Phase III IFl Study - Preliminary Design * To assess the efficacy, safety and tolerability of MAT2203 in patients with serious, life-threatening IFls and limited treatment options «All patients will receive oral MAT2203 as “step down” treatment after initial treatment with IV AMB (or an echinocandin
Slide 11: 2023 Activities Position MAT2203 For Partnering and Commercial Success
2023 Activities Position MAT2203 For Partnering and Commercial Success 2022 RX Strong Phase 2 EnACT cryptococcal meningitis data Lf '* Important Process FDA feedback on Compassionate Use Improvements to Invasive Fungal Cases Reduce COGs Infections Phase 3 Study a ae rr +> De-risk indications beyond
Slide 12: Matinas Investment Thesis
Matinas Investment Thesis ~$28.8 Million Cash at 12/31/22 - Cash Runway EXTENDS into Q2 2024 Substantial UPSIDE =) LNCs Disrupting Nucleic Acid Delivery And Q2 - In vivo biodistribution data with mRNA from BioNTech Collaboration Q2 - Potential BioNTech License Agreement & expansion of established re
Slide 13: Matinas BioPharma Holdings
Matinas BioPharma Holdings (NYSE AMER: MTNB) 1545 Route 206 South Suite 302 Bedminster, NJ 07921 (908) 484-8805 www.matinasbiopharma.com MATINAS BIOPHARMA
Matinas BioPharma Holdings — Corporate Update (January 2023) on 6ix